- Conditions
- Epilepsy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2569–2592
of 81,002
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
- Interventions
- FN-1501
- Drug
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Fairway, Kansas • Detroit, Michigan
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy
- Drug · Procedure
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
- Interventions
- Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Nursing Caries, Arteriovenous Fistula, Simulation-based Training
- Interventions
- simulation-based training
- Other
- Lead sponsor
- University Hospital, Caen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 0
- States / cities
- Not listed
- Conditions
- Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- REGN4659, Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Grand Rapids, Michigan • Charlotte, North Carolina + 3 more
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 139
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 82 more
- Conditions
- Congenital Haemophilia
- Interventions
- Concizumab
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 23
- States / cities
- Los Angeles, California • San Francisco, California • Hartford, Connecticut + 19 more
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Interventions
- PF-04449913 (Glasdegib), Azacitidine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
- Conditions
- Depression, Postpartum
- Interventions
- standardized electronic messages, nurse phone call if requested, Staff nurse phone follow-up
- Behavioral
- Lead sponsor
- Saint Anselm College
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 683 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Manchester, New Hampshire
- Conditions
- Amputation Stumps, Pain
- Interventions
- Procedure/Surgery: Enriched Fat grafting
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Recurrent Melanoma
- Interventions
- selinexor, Correlative studies
- Drug · Other
- Lead sponsor
- Kari Kendra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lymphoma
- Interventions
- Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 80 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Carcinoma, Lumpectomy, Ductal Carcinoma in Situ
- Interventions
- Electronic Brachytherapy, Intracavitary accelerated partial breast irradiation
- Radiation
- Lead sponsor
- Xoft, Inc.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 8
- States / cities
- Tuscaloosa, Alabama • Montebello, California • Orange Park, Florida + 5 more
- Conditions
- Chronic Plaque-type Psoriasis
- Interventions
- AIN457, AIN457A, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more
- Conditions
- Depressive Disorder
- Interventions
- duloxetine hydrochloride
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 32
- States / cities
- Little Rock, Arkansas • Coral Springs, Florida • Jacksonville, Florida + 29 more
- Conditions
- Multiple Myeloma
- Interventions
- Filgrastim, Bortezomib, Carfilzomib, Dexamethasone, Cyclophosphamide, Thalidomide, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Myelodysplastic Syndrome, MDS, Low to Intermediate-1 MDS, Non-deletion 5q
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Chester, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Allogeneic Stem Cell Transplant Recipient
- Interventions
- Fludarabine, Intermediate-dose Total Body Irradiation (TBI), Post-transplant Cyclophosphamide (PTCy), Tacrolimus, Mycophenolate mofetil (MMF)
- Drug · Radiation
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin detemir, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 20
- States / cities
- Fresno, California • Mission Viejo, California • Miami, Florida + 15 more
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Weight Change, Body, Behavior, Health, Obesity, Childhood, Parent-Child Relations
- Interventions
- Brenner mFIT (standard care), Brenner mFIT (standard care plus mobile health components)
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina